Jokanovic Natali, Tan Edwin C K, van den Bosch Denise, Kirkpatrick Carl M, Dooley Michael J, Bell J Simon
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia; Pharmacy Department, Alfred Hospital, Melbourne, Australia.
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia.
Res Social Adm Pharm. 2016 May-Jun;12(3):384-418. doi: 10.1016/j.sapharm.2015.06.007. Epub 2015 Jul 9.
Clinical medication review (CMR) is a structured and collaborative service aimed at identifying and resolving medication-related problems (MRPs). This is the first systematic review of CMR research in Australia.
To systematically review the processes and outcomes of CMR in community-settings in Australia.
MEDLINE, EMBASE, International Pharmaceutical Abstracts (IPA), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Library and the grey literature were searched from 2000 to February 2015. All study designs were considered. Data extraction and quality assessment were performed independently by two investigators.
Nine controlled studies, 34 observational and uncontrolled studies, 11 qualitative studies (focus groups and interviews) and nine survey studies were included. The CMRs resulted in identification of MRPs (n = 15 studies, mean 3.6 MPRs per CMR) and improved adherence (n = 3). Reductions in numbers of medications prescribed (n = 3 studies), hospitalizations (n = 3), potentially inappropriate prescribing (n = 3) and costs (n = 6) were demonstrated. Comparisons to a control group, predominately non-recipients of CMR, were made in eleven of 43 studies. Evidence supports additional models that promote interprofessional collaboration and timely referral following hospital discharge. Qualitative research identified low awareness of CMR among eligible non-recipients, while benefits were perceived to outweigh barriers to implementation. Underserved populations include indigenous and culturally and linguistically diverse people, recipients of palliative care, those recently discharged from hospital, people with poor medication adherence, those in rural and remote areas, older males, and younger people with long-term, persistent or serious health problems.
The available evidence suggests CMR is beneficial in improving the quality use of medications and health outcomes. However, lack of comparator groups in many observational studies limited the strength of conclusions in relation to the impact on clinical outcomes. Addressing access gaps for underserved populations, implementing additional referral pathways, and facilitating greater collaboration between the health professionals represent opportunities for further improvement.
临床用药审查(CMR)是一项结构化的协作服务,旨在识别和解决与用药相关的问题(MRP)。这是对澳大利亚CMR研究的首次系统评价。
系统评价澳大利亚社区环境中CMR的过程和结果。
检索2000年至2015年2月的MEDLINE、EMBASE、国际药学文摘(IPA)、护理学与健康相关文献累积索引(CINAHL)、Cochrane图书馆及灰色文献。纳入所有研究设计。由两名研究人员独立进行数据提取和质量评估。
纳入9项对照研究、34项观察性和非对照研究、11项定性研究(焦点小组和访谈)以及9项调查研究。CMR导致识别出MRP(n = 15项研究,每次CMR平均3.6个MRP)并提高了依从性(n = 3)。显示出所开药物数量(n = 3项研究)、住院次数(n = 3)、潜在不适当处方(n = 3)和费用(n = 6)有所减少。在43项研究中的11项中与对照组进行了比较,对照组主要是未接受CMR的人群。有证据支持促进跨专业协作和出院后及时转诊的其他模式。定性研究发现符合条件的未接受者对CMR的知晓率较低,而认为益处大于实施障碍。服务不足的人群包括原住民以及文化和语言背景多样的人群、姑息治疗接受者、近期出院者、用药依从性差的人群、农村和偏远地区的人群、老年男性以及患有长期、持续性或严重健康问题的年轻人。
现有证据表明CMR有助于改善药物的合理使用和健康结局。然而,许多观察性研究中缺乏对照组限制了有关对临床结局影响的结论的力度。解决服务不足人群的获取差距、实施额外的转诊途径以及促进卫生专业人员之间更大程度的协作是进一步改善的机会。